Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Short term Debt: 2020-2025

Historic Short term Debt for Eton Pharmaceuticals (ETON) over the last 4 years, with Sep 2025 value amounting to $2.8 million.

  • Eton Pharmaceuticals' Short term Debt fell 32.70% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 32.70%. This contributed to the annual value of $5.4 million for FY2023, which is 420.81% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Short term Debt stood at $2.8 million, which was up 0.25% from $2.8 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Short term Debt's 5-year high stood at $5.4 million during Q4 2023, with a 5-year trough of $364,000 in Q2 2022.
  • Over the past 3 years, Eton Pharmaceuticals' median Short term Debt value was $2.8 million (recorded in 2025), while the average stood at $3.2 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Short term Debt slumped by 51.40% in 2022, and later soared by 420.81% in 2023.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Short term Debt stood at $1.4 million in 2021, then fell by 27.15% to $1.0 million in 2022, then skyrocketed by 420.81% to $5.4 million in 2023, then skyrocketed by 167.86% to $4.1 million in 2024, then tumbled by 32.70% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $2.8 million for Q2 2025, and $4.1 million during Q3 2024.